ProShare Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-13,012
| Closed | -$671K | – | 1911 |
|
|
2022
Q3 | $671K | Buy |
13,012
+369
| +3% | +$15.3K | ﹤0.01% | 816 |
|
|
2022
Q2 | $313K | Sell |
12,643
-4,731
| -27% | -$104K | ﹤0.01% | 1199 |
|
|
2022
Q1 | $436K | Sell |
17,374
-4,285
| -20% | -$120K | ﹤0.01% | 1371 |
|
|
2021
Q4 | $788K | Sell |
21,659
-194
| -0.9% | -$6.81K | ﹤0.01% | 1175 |
|
|
2021
Q3 | $374K | Sell |
21,853
-4,687
| -18% | -$73K | ﹤0.01% | 1386 |
|
|
2021
Q2 | $355K | Buy |
26,540
+3,713
| +16% | +$91.5K | ﹤0.01% | 1774 |
|
|
2021
Q1 | $1.17M | Buy |
22,827
+1,170
| +5% | +$70.4K | ﹤0.01% | 905 |
|
|
2020
Q4 | $1.34M | Buy |
21,657
+4,478
| +26% | +$256K | 0.01% | 759 |
|
|
2020
Q3 | $941K | Buy |
17,179
+1,251
| +8% | +$67.4K | ﹤0.01% | 740 |
|
|
2020
Q2 | $916K | Buy |
15,928
+5,521
| +53% | +$300K | ﹤0.01% | 736 |
|
|
2020
Q1 | $418K | Sell |
10,407
-7,717
| -43% | -$328K | ﹤0.01% | 776 |
|
|
2019
Q4 | $717K | Sell |
18,124
-2,283
| -11% | -$40.1K | ﹤0.01% | 923 |
|
|
2019
Q3 | $138K | Buy |
20,407
+1,088
| +6% | +$8.17K | ﹤0.01% | 1502 |
|
|
2019
Q2 | $180K | Sell |
19,319
-287
| -1% | -$3.32K | ﹤0.01% | 1459 |
|
|
2019
Q1 | $272K | Buy |
19,606
+111
| +0.6% | +$1.27K | ﹤0.01% | 1305 |
|
|
2018
Q4 | $213K | Sell |
19,495
-3,799
| -16% | -$40.1K | ﹤0.01% | 1346 |
|
|
2018
Q3 | $294K | Sell |
23,294
-247
| -1% | -$2.98K | ﹤0.01% | 1371 |
|
|
2018
Q2 | $310K | Sell |
23,541
-2,164
| -8% | -$25.9K | ﹤0.01% | 1367 |
|
|
2018
Q1 | $350K | Sell |
25,705
-4,235
| -14% | -$43.7K | ﹤0.01% | 1253 |
|
|
2017
Q4 | $178K | Buy |
29,940
+829
| +3% | +$5.69K | ﹤0.01% | 1666 |
|
|
2017
Q3 | $216K | Buy |
29,111
+2,227
| +8% | +$18.5K | ﹤0.01% | 1262 |
|
|
2017
Q2 | $252K | Sell |
26,884
-1,280
| -5% | -$9.4K | ﹤0.01% | 1253 |
|
|
2017
Q1 | $205K | Sell |
28,164
-7,114
| -20% | -$51.2K | ﹤0.01% | 1443 |
|
|
2016
Q4 | $261K | Buy |
35,278
+2,881
| +9% | +$20.7K | ﹤0.01% | 1456 |
|
|
2016
Q3 | $196K | Sell |
32,397
-5,762
| -15% | -$27.2K | ﹤0.01% | 1348 |
|
|
2016
Q2 | $171K | Buy |
38,159
+2,311
| +6% | +$8.67K | ﹤0.01% | 1458 |
|
|
2016
Q1 | $89K | Sell |
35,848
-3,714
| -9% | -$13.5K | ﹤0.01% | 1528 |
|
|
2015
Q4 | $320K | Buy |
39,562
+3,278
| +9% | +$23.2K | ﹤0.01% | 1259 |
|
|
2015
Q3 | $220K | Sell |
36,284
-2,160
| -6% | -$15.6K | ﹤0.01% | 1276 |
|
|
2015
Q2 | $316K | Sell |
38,444
-1,758
| -4% | -$14K | ﹤0.01% | 1289 |
|
|
2015
Q1 | $304K | Buy |
40,202
+5,740
| +17% | +$44.9K | ﹤0.01% | 1466 |
|
|
2014
Q4 | $235K | Buy |
34,462
+1,395
| +4% | +$7.38K | ﹤0.01% | 1668 |
|
|
2014
Q3 | $149K | Sell |
33,067
-6,360
| -16% | -$33.6K | ﹤0.01% | 2076 |
|
|
2014
Q2 | $231K | Sell |
39,427
-18,282
| -32% | -$103K | ﹤0.01% | 2089 |
|
|
2014
Q1 | $383K | Buy |
57,709
+37,080
| +180% | +$258K | ﹤0.01% | 2073 |
|
|
2013
Q4 | $119K | Buy |
20,629
+5,099
| +33% | +$26.3K | ﹤0.01% | 1298 |
|
|
2013
Q3 | $86K | Buy |
+15,530
| New | +$168K | ﹤0.01% | 2451 |
|
Other funds holding CCXI
ProShare Advisors's CCXI Position: Q4 2022 in Review
ProShare Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 13,012 shares — an estimated $671K sold.
ProShare Advisors first reported a position in CCXI in Q3 2013 and held it in 37 quarters. The position peaked at $1.34M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- ProShare Advisors reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- ProShare Advisors sold 13,012 ChemoCentryx, Inc. shares in Q4 2022, an estimated $671K.
- ProShare Advisors first reported a position in ChemoCentryx, Inc. in Q3 2013 and held it in 37 quarters.
- ProShare Advisors's ChemoCentryx, Inc. position peaked at $1.34M in Q4 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on ProShare Advisors's 13F filing for Q4 2022, filed 2 Feb 2023.